NAD+ therapy claims: what the science says vs. TikTok hype

What did @krystaln888 actually say?

She said she felt "amazing" within two days of her first NAD+ dose, reporting better mood, better energy, and "mental clarity." Her exact words: "I never thought this would happen." She framed this as immediate, undeniable, and personal proof. To her credit, she asked viewers whether she was "going crazy" rather than presenting this as settled medicine. The video caption added claims about "cell repair / anti-aging support" that went further than her spoken words.

It is worth separating what she personally reported, which is an anecdote about how she felt, from the caption's clinical-sounding bullet points. Those are two different things with different standards of evidence. The spoken content was more honest. The caption oversold it.

Does the science back this up?

NAD+ has real, peer-reviewed research behind it, but the picture is messier than a two-day personal testimonial suggests. The honest answer is: promising preclinical data, genuinely interesting early human trials, and a long way to go before the caption-level claims are proven.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in mitochondrial energy metabolism and DNA repair pathways. Declining NAD+ levels with age are well-documented (Verdin, 2015, Science). Supplementation via precursors like NMN and NR has shown measurable effects on NAD+ tissue levels in humans (Yoshino et al., 2021, Science). Intravenous NAD+ administration, which appears to be what she took based on context, does raise blood NAD+ faster than oral routes.

On mood and energy specifically: a small open-label study by Braidy et al. (2019, Nutrients) reported subjective energy improvements in participants taking NAD+ precursors, but open-label studies without placebo controls are weak evidence. No large randomized controlled trial has confirmed that a single NAD+ infusion reliably produces the kind of rapid mood and energy response she described.

What did they get wrong (or right)?

She got the basic mechanism roughly right. NAD+ is genuinely involved in energy production and cellular repair. She did not invent that. The caption's "anti-aging support" framing is where things slip from "plausible" into marketing language. There is no human clinical evidence that NAD+ supplementation slows aging in the way that phrase implies to a general audience.

The bigger problem is the "felt it after ONE" framing. This is a well-known issue with infusion therapies: patients frequently report feeling noticeably energized or mood-lifted during or immediately after IV therapy, and researchers have attributed much of this to the experience itself, including the placebo response, the act of resting for an infusion, and hydration effects (Apsley et al., 2019, Journal of Molecular and Genetic Medicine). That does not mean her experience was fake. It means her experience is not evidence of a specific pharmacological effect within 48 hours.

She also casually mentioned moving on to GHK-Cu next, implying a personal stacking approach without any clinical oversight discussion. That is worth flagging even if she did not explicitly recommend it to viewers.

What should you actually know?

NAD+ therapy is not a fringe idea. It has enough mechanistic and early human evidence to be taken seriously by researchers. But the gap between "this has interesting science" and "I felt it after one dose" is large, and filling that gap with personal enthusiasm is how supplement culture misleads people who are genuinely trying to make informed decisions.

If you are considering NAD+ therapy, the questions worth asking are: what route of administration, what dose, what is the source, and is a licensed provider monitoring your response. IV NAD+ can cause side effects during infusion including nausea, flushing, and chest tightness. These are not rare and are not mentioned in the video.

The "peptide" hashtag used in the caption is also worth noting. NAD+ is not a peptide. It is a coenzyme. Grouping it with BPC-157 or GHK-Cu in the same optimization category conflates compounds with very different regulatory statuses, mechanisms, and evidence bases. That kind of category blurring makes it harder for viewers to evaluate what they are actually considering.